4 news items
Expert Outlook: Sutro Biopharma Through The Eyes Of 10 Analysts
STRO
8 May 24
to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
STRO
2 Apr 24
the amount of payload that reaches non-tumor tissue.2 Under the terms of the agreement, Ipsen will assume responsibility
Navigating 4 Analyst Ratings For Sutro Biopharma
STRO
27 Mar 24
$12.00
$16.00
Key Insights:
Action Taken: In response to dynamic market
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
STRO
25 Mar 24
leadership team through the promotion of Jane Chung to President and Chief Operating Officer, a newly created role in which she will be responsible
- Prev
- 1
- Next